Psicoterapia assistida por cetamina no tratamento da depressão resistente
Revista Eletrônica Acervo Científico October 7, 2025 Tainá Zen Loss, Carolina Radaelli Fucina, Denise Bergamo Schenato et al.
Ketamine, an NMDA receptor antagonist, produces rapid antidepressant effects in subanesthetic doses administered intravenously or intranasally, with benefits lasting days to weeks. Treatment-resistant depression persists after at least two adequate antidepressant trials and is linked to functional impairment, prolonged emotional distress, and increased suicide risk. Early evidence suggests that ketamine-assisted psychotherapy may reduce relapses, improve functioning, and extend benefits, representing a paradigm shift by combining rapid symptom relief with positive impacts on quality of life and emotional resilience. This synergistic pharmacological and psychotherapeutic approach offers a promising strategy for treatment-resistant depression and may redefine its clinical management.